Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function
Study Details
Study Description
Brief Summary
The primary objective is to evaluate pharmacokinetics of Fluzoparib and its main metabolite in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.
The secondary objective is to evaluate the safety of Fluzoparib in subjects with mild and moderate renal impairment and in healthy subjects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group A
|
Drug: Fluzoparib
Normal Renal Function:A single oral dose of Fluzoparib will be administered.
|
| Experimental: Group B
|
Drug: Fluzoparib
Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
|
| Experimental: Group C
|
Drug: Fluzoparib
Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
|
Outcome Measures
Primary Outcome Measures
- Pharmacokinetics parameters of Fluzoparib: Cmax [96 hours post dose]
- Pharmacokinetics parameters of Fluzoparib: AUC0-t [96 hours post dose]
- Pharmacokinetics parameters of Fluzoparib: AUC0-∞ (if available) [96 hours post dose]
- Pharmacokinetics parameters of main metabolite (SHR165202) of Fluzoparib: Cmax [96 hours post dose]
- Pharmacokinetics parameters of main metabolite (SHR165202) of Fluzoparib: AUC0-t [96 hours post dose]
- Pharmacokinetics parameters of main metabolite (SHR165202) of Fluzoparib: AUC0-∞ (if available) [96 hours post dose]
Secondary Outcome Measures
- Other pharmacokinetics parameters of Fluzoparib: Tmax [96 hours post dose]
- Other pharmacokinetics parameters of main metabolite (SHR165202) of Fluzoparib: Tmax [96 hours post dose]
- Plasma protein binding rate of Fluzoparib [Day 01 post dose]
- Plasma protein binding rate of main metabolite (SHR165202) of Fluzoparib [Day 01 post dose]
- The incidence and severity of adverse events/serious adverse events (based on NCI-CTCAE 5.0) [19 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
Inclusion Criteria for subjects with impaired kidney function:
-
Sign the informed consent before the trial, and fully understand the content, process, and possible adverse reactions of the trial;
-
Male or female subjects aged 18 to 70 (including 18 and 70);
-
Body mass index (BMI) ranges from 18 kg/m2 to 28 kg/m2 (including 18 and 28);
-
The glomerular filtration rate should meet the following criteria (GFR, mL/min):Subjects with mild renal impairment (CKD2): 60-89 mL/min (including 60-89);Subjects with moderate renal impairment (CKD3): 30-59 mL/min (including 30-59 ends);
-
Renal function should be stable, and the GFR results should be tested twice before administration (at least 3 days apart) within the same CKD stage.
Inclusion Criteria for subjects with normal kidney function:
-
Sign the informed consent before the trial and fully understand the content, process, and possible adverse reactions of the trial;
-
Male or female subjects aged 18 to 70 (including 18 and 70);
-
Body mass index (BMI) ranges from 18 kg/m2 to 28 kg/m2 (including 18 and 28);
-
Glomerular filtration rate (GFR) ≥90 mL/min.
Exclusion Criteria:
Exclusion Criteria for subjects with impaired kidney function:
-
History of kidney transplant;
-
Need Renal dialysis during the study;
-
Urinary incontinence or anuria;
-
Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms (female) or QTcF≥450 ms (male) within 12 months before the start of treatment;
-
Received any investigational drug within 3 months before the study started;
-
Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the study started;
-
Smokers and alcoholics, or those screened positive for alcohol;
-
History of drug use, or drug abuse screening positive.
Exclusion Criteria for subjects with normal kidney function:
-
History of kidney transplant;
-
Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms (female) or QTcF≥450 ms (male) within 12 months before the start of treatment;
-
Received any investigational drug within 3 months before the study started;
-
Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the study started;
-
Smokers and alcoholics, or those screened positive for alcohol;
-
History of drug use, or drug abuse screening positive.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SHR3162-I-119